Lapatinib is a medication used to treat HER2-positive breast cancer. It is approved as a standalone treatment as well as combination therapy along with capecitabine. Suppliers of lapatinib market it in the form of 250mg tablets. GlaxoSmithKline is the developer and earliest manufacturer of lapatinib medications. On March 13, 2007, the FDA gave its approval for use in combination with the chemotherapeutic medication capecitabine in patients with locally advanced cancer. It was first granted marketing authorization by the FDA, and is currently approved in over 100 countries worldwide, including but not limited to Japan, Brazil, Australia, India and across Europe. The largest lapatinib manufacturers and suppliers are companies Genentech, Novartis, and Pfizer, whereas the largest supplier of lapatinib globally is GlaxoSmithKline, who markets it under the trade names Tyverb and Tykerb.

With a dissociation half-life of about 300 minutes, lapatinib is a 4-anilinoquinazoline kinase antagonist of the cytoplasmic tyrosine kinase regions of both epidermal growth factor and human epidermal growth receptor type 2. In vitro as well as in several animal models, lapatinib suppresses the proliferation of ERBB-driven tumour cells. Lapatinib and 5-florouracil, the active form of capecitabine, were combined in the 4 tumour cell lines evaluated in an in vitro investigation, and the results showed an additive impact. In trastuzumab-conditioned cell lines, lapatinib's effects on growth inhibition were assessed. Breast cancer cell lines chosen for long-term growth on trastuzumab-containing media in vitro still shown significant activity against lapatinib. These in vitro results imply that there is no pass between these two medications. Lapatinib is a kinase inhibitor that belongs to the 4-anilinoquinazoline class of small molecules. GlaxoSmithKline created the anti-cancer medication lapatinib as a therapy for tumours like breast and lung cancer.

Lapatinib is available for sale from various Lapatinib vendors at various costs. The retail prices per 70 (250mg) tablets of lapatinib fall into an approximate range of 1,100 EUR to 1,200 EUR. The prices of Lapatinib medications vary depending on the concentration of active ingredients in the formulation as well as supplier and manufacturer pricing. Also, the costs of Lapatinib vary depending on manufacturer and supplier pricing, whether it is a generic or trade name formulation, concentration of the active ingredient in the formulation. Lapatinib suppliers, on the whole, are in favor of patient aid initiatives. The price of Lapatinib is higher than that of such substitutes, owing largely to the more costly manufacturing process needed to produce it.

Making use of Pipelinepharma's worldwide B2B online marketplace for medications and other pharmaceuticals is the ideal approach to locate and acquire access to Lapatinib manufacturers and suppliers. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified Lapatinib manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform. Finding reliable suppliers and manufacturers of particular medications like Lapatinib can typically be a time-consuming challenge, but with Pipelinepharma's straightforward search engine and network of tested partners, the entire process becomes much simpler. Utilizing our built-in search engine, all you have to do to begin going is start looking for potential Lapatinib suppliers or manufacturers. You may also use filters to narrow down your search results and look for Lapatinib from particular nations.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Lapatinib offerings can be narrowed down with filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for this substance manufacturer and Lapatinib suppliers that you are looking for. These also enable you to check the dossier status of this medicine and the GMP approvals of the different variants of Lapatinib. Also, each manufacturer or supplier product description contains essential information about this substance, including clinical data, stability zones, and countries in which Lapatinib is already registered. Manufacturers also have special delivery terms.

Suppose you are a pharmaceutical licensing company or a distributor. In that case, you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the Lapatinib suppliers. This way, the marketplace allows you as a distributor to skip the process of making a list of product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are boarded on the platform. This allows us to screen Lapatinib manufacturers for the quality of the pharmaceutical products' dossiers and protect against the risk of possible malpractices.